Menu
Search
|

Menu

Close
X

Exelixis Inc EXEL.OQ (NASDAQ Stock Exchange Global Select Market)

23.22 USD
-1.06 (-4.37%)
As of Mar 22
chart
Previous Close 24.28
Open 24.20
Volume 743,942
3m Avg Volume 1,227,922
Today’s High 24.36
Today’s Low 23.22
52 Week High 25.31
52 Week Low 13.43
Shares Outstanding (mil) 300.13
Market Capitalization (mil) 6,969.01
Forward P/E 10.50
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.08 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
854
FY17
452
FY16
191
EPS (USD)
FY18
2.212
FY17
0.494
FY16
-0.333
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
10.50
58.10
Price to Sales (TTM)
vs sector
8.16
8.84
Price to Book (MRQ)
vs sector
5.41
4.60
Price to Cash Flow (TTM)
vs sector
9.99
40.07
Total Debt to Equity (MRQ)
vs sector
0.01
17.66
LT Debt to Equity (MRQ)
vs sector
0.01
13.97
Return on Investment (TTM)
vs sector
74.32
12.12
Return on Equity (TTM)
vs sector
87.77
13.24

EXECUTIVE LEADERSHIP

Stelios Papadopoulos
Independent Chairman of the Board, Co-Founder, Since 1998
Salary: --
Bonus: --
Michael Morrissey
President, Chief Executive Officer, Director, Since 2010
Salary: $891,781.00
Bonus: $675,750.00
Christopher Senner
Chief Financial Officer, Executive Vice President, Since 2015
Salary: $562,120.00
Bonus: $255,150.00
Gisela Schwab
President - Product Development and Medical Affairs, Chief Medical Officer, Since 2016
Salary: $629,493.00
Bonus: $318,000.00
Peter Lamb
Executive Vice President - Scientific Strategy, Chief Scientific Officer, Since 2016
Salary: $473,190.00
Bonus: $214,245.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1851 Harbor Bay Pkwy
ALAMEDA   CA   94502-3016

Phone: +1650.8377000

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

SPONSORED STORIES